Showing results (2661-2670 of 6,166) with videos related to
Sort By:
Pageof 617
Nature Medicine|February 8, 2019
Precision epidemiology for infectious disease controlJason T Ladner, Nathan D Grubaugh, Oliver G Pybus, et al.Nature Medicine|September 8, 2020
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trialRobert J Motzer, Paul B Robbins, Thomas Powles, et al.Nature Medicine|September 10, 2020
Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosisAdam G Laing, Anna Lorenc, Irene Del Molino Del Barrio, et al.Nature Medicine|September 15, 2020
Seasonal coronavirus protective immunity is short-lastingArthur W D Edridge, Joanna Kaczorowska, Alexis C R Hoste, et al.Nature Medicine|January 15, 2020
Phenome-based approach identifies RIC1-linked Mendelian syndrome through zebrafish models, biobank associations and clinical studiesGokhan Unlu, Xinzi Qi, Eric R Gamazon, et al.Nature Medicine|January 15, 2020
Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilizationNoa Dagan, Eldad Elnekave, Noam Barda, et al.Nature Medicine|January 15, 2020
Axes of a revolution: challenges and promises of big data in healthcareSmadar Shilo, Hagai Rossman, Eran SegalNature Medicine|April 7, 2020
A neuroimaging biomarker for striatal dysfunction in schizophreniaAng Li, Andrew Zalesky, Weihua Yue, et al.Nature Medicine|April 2, 2020
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedoniaAndrew D Krystal, Diego A Pizzagalli, Moria Smoski, et al.Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.Pageof 617